INFI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt

infinity pharmaceuticals inc (INFI) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INFINITY PHARMACEUTICALS INC (INFI)
\

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

25 Employees
Last Reported Date: 03/14/19

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman & CEO
Total Annual Compensation: $1.2M
President
Total Annual Compensation: $719.7K
Chief Medical Officer
Total Annual Compensation: $1.0M
VP, General Counsel & Secretary
Total Annual Compensation: $671.6K
Senior VP & Chief Scientific Officer
Total Annual Compensation: $596.0K
Compensation as of Fiscal Year 2018.
infinity pharmaceuticals inc
Infinity Pharmaceuticals Intends To Seek Acquisitions

Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) will look for acquisitions. Infinity Pharmaceuticals has filed a Follow-on Equity Offering in the amount of $20 million. We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include research and development expenses, including costs related to clinical trials, regulatory submissions, and manufacturing; general and administrative expenses; the acquisition of companies, businesses, or their assets; the repayment and refinancing of debt; working capital; and capital expenditures.

Infinity Pharmaceuticals, Inc. Presents at 2019 BIO International Conference, Jun-03-2019 through Jun-06-2019

Infinity Pharmaceuticals, Inc. Presents at 2019 BIO International Conference, Jun-03-2019 through Jun-06-2019. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Presentation Date & Speakers: Jun-04-2019, Adelene Q. Perkins, Chairman & CEO. Jun-05-2019, Samuel Agresta, Chief Medical Officer.

Infinity Pharmaceuticals, Inc Announces Unaudited Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2019; Provides Earnings Guidance for the Year 2019

Infinity Pharmaceuticals, Inc. announced unaudited consolidated unaudited earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported total revenue was $2,142,000. Loss from operations was $13,783,000 compared with $9,517,000 a year ago. Net loss was $13,744,000 compared with $9,451,000 a year ago. Basic and diluted loss per common share were $0.24 compared with $0.18 a year ago. For the year 2019, the company expected net loss for 2019 to range from $40 million to $50 million including the Copiktra royalty monetization.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INFI.
View Industry Companies
 

Industry Analysis

INFI

Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact INFINITY PHARMACEUTICALS INC, please visit www.infi.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.